Arcus Biosciences, Inc. reports developments as a clinical-stage global biopharmaceutical company developing differentiated molecules and combination therapies for cancer and inflammatory and autoimmune diseases. Company news commonly covers quarterly financial results, pipeline updates, clinical program strategy, data presentations and changes in research priorities across its investigational portfolio.
Recurring updates focus on casdatifan, a HIF-2a inhibitor for clear cell renal cell carcinoma, quemliclustat, a small-molecule CD73 inhibitor for pancreatic cancer, and earlier inflammation programs such as AB102, an MRGPRX2 antagonist. Arcus also issues routine corporate announcements on employment inducement grants, investor conference participation and collaboration-related developments.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Arcus Biosciences, Inc. (NYSE:RCUS), a biopharmaceutical company focused on cancer treatments, announced the grant of equity awards to six new employees. The awards include options to purchase a total of 17,600 shares at an exercise price of $19.31 as of April 24, 2023. Additionally, they received restricted stock units for 8,800 shares, under the 2020 Inducement Plan approved in January 2020.
The company aims to develop innovative cancer therapies in collaboration with industry partners and has six investigational medicines in clinical studies targeting various biological pathways.